Home Medicine Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
Article
Licensed
Unlicensed Requires Authentication

Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis

  • Junaidi Khotib EMAIL logo , Asri Putri Pratiwi , Chrismawan Ardianto and Mahardian Rahmadi
Published/Copyright: January 11, 2020
Journal of Basic and Clinical Physiology and Pharmacology
From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 30 Issue 6

Abstract

Background

Osteoarthritis (OA) is the most prevalent joint disease and a common cause of joint pain, functional loss, and disability. The severity of this disease is always associated with increased levels of proinflammatory cytokines, which play an important role in cartilage damage, synovitis, and other damage to joint tissues. The discovery that many soluble mediators such as cytokines or prostaglandins can increase the production of matrix metalloproteinases by chondrocytes led to the first steps of an inflammatory state. Several studies show that cytokines, such as interleukin 1ß, have a major role in the development of inflammation that occurs in these joints. The use of glucosamine as an adjuvant to meloxicam therapy is expected to inhibit the development of inflammatory OA.

Methods

The OA model in rat was induced by single injection of intraarticular monosodium iodoacetate (MIA). The development of OA was observed for 21 days. Furthermore, the evaluation of glucosamine potency as an adjuvant of meloxicam therapy for reducing IL-1ß was done by combined treatment at a low dose of meloxicam 1 mg/kg BW with glucosamine at a dose of 125, 250, or 500 mg/kg BW orally for 28 days. Response to hyperalgesia and knee joint diameter was measured on days 0, 7, 14, 21, 28, 35, 42, and 49. IL-1ß levels were measured on day 21 and day 49 after MIA injection.

Results

MIA injection successfully induced OA as marked by a significant difference in the time of latency to heat stimulus (p < 0.01) and a significant increase in joint diameter (p < 0.01). On day 21, IL-1ß levels showed a significant decrease in MIA injection (p = 0.05). The administration of meloxicam and glucosamine did not induce significant decrease in knee joint diameter (p > 0.10), but was able to significantly increase the latency time to heat stimulus (p < 0.01). IL-1ß levels also showed a significant decrease after administering a combination of glucosamine and meloxicam (p < 0.01).

Conclusions

Taken together, the use of glucosamine as an adjuvant in meloxicam therapy may be caused by the synergistic mechanism of meloxicam for the attenuation of OA development through systemically reducing IL-1ß.

Keywords: glucosamine; IL-1ß; meloxicam; MIA; osteoarthritis

Acknowledgments

The author thanks the Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga for all supporting during the research.

  1. Research funding: This research was funded by the Ministri of Research, Technology and Higher Education, Republic of Indonesia through a scheme of Mandate Research Grant.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Ethical approval: All experiments were performed at the Animal Research Laboratory of Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia in accordance with the guide for care and use of laboratory animal issued by National Institute of Health revised in 1985. The protocol of this reseach was approved by the Ethical Committee of Faculty of Veterinary, Universitas Airlangga.

References

[1] Parker JN, Parker PM. The official patient’s sourcebook on osteoarthritis. United States of America: ICON Health Publications, 2003:9–44.Search in Google Scholar

[2] Tanna S. Priority Medicines for Europe and the World. “A Public Health Approach to Innovation”. Update on 2004 Background Paper Background Paper 6.12 Osteoarthritis, 2013:6–9.Search in Google Scholar

[3] Melo-Florián A. IL-1 and its role in osteoarthritis. Open J Med 2011;1:1–6.Search in Google Scholar

[4] Felson DT, Schaible HG. Pain in osteoarthritis. United States of America: Wiley-Blackwell, 2009:10–27.Search in Google Scholar

[5] Maulina M. Kerusakan proteoglikan pada osteoartritis. Jurnal Ilmiah Sains, Teknologi, Ekonomi, Sosial dan Budaya, 2017;1:61–7.Search in Google Scholar

[6] Leong DJ, Choudhury M, Hirsh DM, Hardin JA, Cobelli NJ, Sun HB. Review nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis. Int J Mol Sci 2013;14:23063–85.10.3390/ijms141123063Search in Google Scholar PubMed PubMed Central

[7] Mahajan A, Verma S, Tandon V. Osteoarthritis. J Assoc Physician India 2013;3:634–41.Search in Google Scholar

[8] Mabey T, Honsawek S. Cytokines as biochemical markers for knee osteoarthritis. World J Orthop 2015;6:95–105.10.5312/wjo.v6.i1.95Search in Google Scholar PubMed PubMed Central

[9] Michon M, Sellam J, Berenbaum F. Targeted treatment of the rheumatic siseases, 1st ed. United Kingdom: Saunders, An Imprint of Elsevier Inc, 2010:10–30.Search in Google Scholar

[10] Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008;38:165–87.10.1016/j.semarthrit.2007.10.004Search in Google Scholar PubMed

[11] Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. United Kingdom: Queen’s Printer and Controller of HMSO, 2008:40–52.10.3310/hta12110Search in Google Scholar

[12] Smith HS, Baird W. Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population. Am J Hosp Palliat Care 2003;20:297–306.10.1177/104990910302000413Search in Google Scholar PubMed

[13] Mutiatikum D, Rami M. Profil disolusi dan penetapan kadar tablet meloksikam inovator dan generik bermerek dengan KCKT (kromatografi cair kinerja tinggi). Buku Penelitan Kesehatan 2010;38:140–6.Search in Google Scholar

[14] Lisboa FA, Bradley MJ, Hueman MT, Schobel SA, Gaucher BJ, Styrmisdottir EL, et al. Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds. Surgery 2017;4:1164–73.10.1016/j.surg.2016.10.011Search in Google Scholar PubMed

[15] Gregory PJ, Sperry M, Wilson F. Dietary supplements for osteoarthritis. Am Fam Physician 2008;77:177.Search in Google Scholar

[16] Wang Y, Prentice LF, Vitetta L, Wluka AE, Cicuttini FM. The effect of nutritional supplements on osteoarthritis. Altern Med Rev 2004;9:275–96.Search in Google Scholar

[17] Kucharz EJ, Kovalenko V, Szántó S, Bruyère O, Cooper C, Reginster J-Y. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016;32:997–1004.10.1185/03007995.2016.1154521Search in Google Scholar PubMed

[18] Shahine EM, Elhadidi AS. Efficacy of glucosamine sulfate in lowering serum level of interleukin-1ß in symptomatic primary knee osteoarthritis: clinical and laboratory study. Alex J Med 2014;50:159–63.10.1016/j.ajme.2014.01.006Search in Google Scholar

[19] Susan MN. Penggunaan Dam Penanganan Hewan Coba Rodensi Dalam Penelitian Sesuai Dengan Kesejahteraan Hewan. Bogor: Pusat Penelitian Dan Pengembangan Peternakan, 2016:5–14.Search in Google Scholar

[20] Nagy E, Vajda E, Vari C, Sipka S, Farr AM, Horvath E. Meloxicam ameliorates the cartilage and subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritis. Peer J 2017;5:1–19.10.7717/peerj.3185Search in Google Scholar PubMed PubMed Central

[21] Hadiwidjaja S. Pengaruh interleukin-1ß (IL-1ß) dan tumor necrosis factor-a (TNF-a) terhadap dopamin pada cerebral palsy. Bioteknologi 2004;1:25–9.10.13057/biotek/c010105Search in Google Scholar

[22] Pitcher T, Valente JS, Malcangio M. The monoiodoacetate model of osteoarthritis pain in the mouse. J Vis Exp 2016;111:1–5.10.3791/53746Search in Google Scholar PubMed PubMed Central

[23] Puvvadi S, Subrahmanyam CV, Juturu T, Manavalan R, Valliapan K. Solubility of meloxicam in mixed solvent systems. Ethiop Pharm J 2007;25:23–8.10.4314/epj.v25i1.35111Search in Google Scholar

[24] Seedher N, Bhatia S. Solubility enhancement of COX-2 inhibitor using various solvent systems. AAPS 2003;4:1–9.10.1208/pt040333Search in Google Scholar PubMed PubMed Central

[25] Cahyono E, Suptijah P, Wientarsih I. Development of a pressurized hydrolysis method for producing glucosamine. Asian J Agric Food Sci 2014;2:390–6.Search in Google Scholar

[26] Moilanen LJ, Hamalainen M, Nummenmaa E, Ilmarinen P, Vuolteenaho K, Nieminen RM, et al. Monosodium iodoacetate-induced inflammation and joint pain are reduced in TRPA1 deficient mice e potential role of TRPA1 in osteoarthritis. Osteoarthritis Research Society International 2015;23:2017–26.10.1016/j.joca.2015.09.008Search in Google Scholar PubMed

[27] Yamada EF, Salgueiro AF, Goulart AS, Mendes VP, Anjos BL, Folmer V, et al. Evaluation of monosodium iodoacetate dosage to induce knee osteoarthritis: relation with oxidative stress and pain. Int J Rheum Dis 2018;22:1–12.10.1111/1756-185X.13450Search in Google Scholar PubMed

[28] Orita S, Ishikawa T, Miyagi M, Ochiai N, Inoue G, Eguchi Y, et al. Pain related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord 2011;12:1–12.10.1186/1471-2474-12-134Search in Google Scholar PubMed PubMed Central

[29] Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. Therapy 2010;7:591–604.10.2217/thy.10.67Search in Google Scholar

[30] Zulkarnain BS, Suharjono, Suprapti B. Efek antinociceptif gaba agonis gabapentin terhadap nyeri neuropati pada hewan coba mencit. Jurnal Penelitian Medik Eksakta, 2008;7:23–30.Search in Google Scholar

Received: 2019-11-05
Accepted: 2019-11-27
Published Online: 2020-01-11

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Reviews
  2. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
  3. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
  4. Original Articles
  5. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation
  6. Evaluating current practices and policies in the use of injectable medicines for treating myalgia in a primary care center in Pamekasan, Indonesia
  7. The contemporary role and potential of pharmacist contribution for community health using social media
  8. Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
  9. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting
  10. Factors affecting community pharmacist’s service for women with chronic diseases during pregnancy and breastfeeding: application of the Health Belief Model
  11. Overview of therapeutic changes in antiepileptic drugs in adult patients
  12. Exploration of barriers affecting job satisfaction among community pharmacists
  13. Patients’ characteristics and their adherence to insulin therapy
  14. Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients
  15. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia
  16. Translation, cultural adaptation, and validation of the quality of well being self-administered questionnaire in general population in Indonesia
  17. Knowledge, attitude, and practice of pharmacists towards management of hypertension in primary care centers
  18. Medication adherence in diabetes mellitus patients at Tanjung Karang Primary Health Care Center, Mataram
  19. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2
  20. Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole
  21. The effect of curcuma (Curcuma xanthorrizha roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension
  22. Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model
  23. Medical problems in patients with chronic kidney disease undergoing hemodialysis and their therapy
  24. ADMET properties of novel 5-O-benzoylpinostrobin derivatives
  25. Development of nonalcoholic fatty liver disease model by high-fat diet in rats
  26. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor
  27. The relationship between the level of education and accuracy of insulin injection techniques in DM patients with measurement of HbA1c values
  28. The effect of premixed insulin to blood glucose concentration in patients with type 2 diabetes mellitus
  29. Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness
  30. Adherence behavior assessment of oral antidiabetic medication use: a study of patient decisions in long-term disease management in primary health care centers in Surabaya
  31. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma
  32. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients
  33. Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line
  34. The enhancement of Arg1 and activated ERβ expression in microglia HMC3 by induction of 96% ethanol extract of Marsilea crenata Presl. leaves
  35. Ternary solid dispersion to improve solubility and dissolution of meloxicam
  36. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide
  37. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors
  38. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis
  39. Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
  40. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: weighing clinical risk and benefit
  41. Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers
  42. Profile of sociodemographics, sources of infection, antiretrovirals and CD4 counts on HIV/AIDS outpatients in Turen Primary Health Centre, Indonesia
  43. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
  44. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method
  45. Knowledge and attitude: two fundamental factors that determine patient compliance in antibiotic therapy
  46. Molecular docking study of sappan wood extract to inhibit PBP2A enzyme on methicillin-resistant Staphylococcus aureus (MRSA)
  47. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.)
  48. Case Report
  49. A case report of generalized tetanus in a 42-year-old man with dental infection
https://doi.org/10.1515/jbcpp-2019-0332
Keywords for this article
glucosamine; IL-1ß; meloxicam; MIA; osteoarthritis

Articles in the same Issue

  1. Reviews
  2. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
  3. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
  4. Original Articles
  5. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation
  6. Evaluating current practices and policies in the use of injectable medicines for treating myalgia in a primary care center in Pamekasan, Indonesia
  7. The contemporary role and potential of pharmacist contribution for community health using social media
  8. Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
  9. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting
  10. Factors affecting community pharmacist’s service for women with chronic diseases during pregnancy and breastfeeding: application of the Health Belief Model
  11. Overview of therapeutic changes in antiepileptic drugs in adult patients
  12. Exploration of barriers affecting job satisfaction among community pharmacists
  13. Patients’ characteristics and their adherence to insulin therapy
  14. Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients
  15. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia
  16. Translation, cultural adaptation, and validation of the quality of well being self-administered questionnaire in general population in Indonesia
  17. Knowledge, attitude, and practice of pharmacists towards management of hypertension in primary care centers
  18. Medication adherence in diabetes mellitus patients at Tanjung Karang Primary Health Care Center, Mataram
  19. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2
  20. Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole
  21. The effect of curcuma (Curcuma xanthorrizha roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension
  22. Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model
  23. Medical problems in patients with chronic kidney disease undergoing hemodialysis and their therapy
  24. ADMET properties of novel 5-O-benzoylpinostrobin derivatives
  25. Development of nonalcoholic fatty liver disease model by high-fat diet in rats
  26. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor
  27. The relationship between the level of education and accuracy of insulin injection techniques in DM patients with measurement of HbA1c values
  28. The effect of premixed insulin to blood glucose concentration in patients with type 2 diabetes mellitus
  29. Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness
  30. Adherence behavior assessment of oral antidiabetic medication use: a study of patient decisions in long-term disease management in primary health care centers in Surabaya
  31. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma
  32. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients
  33. Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line
  34. The enhancement of Arg1 and activated ERβ expression in microglia HMC3 by induction of 96% ethanol extract of Marsilea crenata Presl. leaves
  35. Ternary solid dispersion to improve solubility and dissolution of meloxicam
  36. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide
  37. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors
  38. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis
  39. Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
  40. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: weighing clinical risk and benefit
  41. Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers
  42. Profile of sociodemographics, sources of infection, antiretrovirals and CD4 counts on HIV/AIDS outpatients in Turen Primary Health Centre, Indonesia
  43. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
  44. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method
  45. Knowledge and attitude: two fundamental factors that determine patient compliance in antibiotic therapy
  46. Molecular docking study of sappan wood extract to inhibit PBP2A enzyme on methicillin-resistant Staphylococcus aureus (MRSA)
  47. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.)
  48. Case Report
  49. A case report of generalized tetanus in a 42-year-old man with dental infection
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Winner of the OpenAthens UX Award 2026
Winner of the OpenAthens UX Award 2026
Have an idea on how to improve our website?
Please write us.
© 2026 De Gruyter Brill
Downloaded on 4.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2019-0332/html
Scroll to top button